



## ESPERITE N.V. issues convertible loan to CEO Frédéric Amar

Zutphen, The Netherlands – 23 December 2015

**ESPERITE N.V.** (Euronext: ESP, 'ESPERITE', or 'the Group') announces the issuance of a convertible loan note of EUR 925,565 to Mr. Frédéric Amar, ESPERITE's Chief Executive Officer and largest shareholder. The issuance converts a payment obligation that ESPERITE has towards Mr. Amar relating to remuneration and pre-paid investments and expenses into the note. Mr. Amar has not participated in the decision-making of the Board of Directors regarding the issuance of the note.

The unsecured convertible loan note will bear interest at a rate of 7% per year, payable annually in arrears on 31 December and be convertible into ESPERITE shares from 31 December 2016 (or at the earlier occurrence of a limited number of events) until maturity at an initial conversion price of EUR 1.89. This initial conversion price equals ESPERITE's share price at the time the possible issuance of the note was being discussed and negotiated between the non-executive directors and Mr. Amar. The conversion price may be adjusted in a limited number of customary circumstances. The note will mature on 31 December 2018, unless earlier converted or repurchased. The note will not be listed.

### About ESPERITE

ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

To learn more about ESPERITE Group, or to book an interview with CEO Frédéric Amar: [+31 575 548 998](tel:+31575548998) - [ir@esperite.com](mailto:ir@esperite.com) or visit the websites at [www.esperite.com](http://www.esperite.com) and [www.genoma.com](http://www.genoma.com).